Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug
Biomedicines,
Год журнала:
2025,
Номер
13(2), С. 422 - 422
Опубликована: Фев. 10, 2025
The
intricate
relationship
between
anticancer
drugs
and
the
gut
microbiome
influences
cancer
treatment
outcomes.
This
review
paper
focuses
on
role
of
integrity
in
enhancing
efficacy
safety
drug
therapy,
emphasizing
pharmacokinetic
interactions
microbiota.
It
explores
how
disruptions
to
composition,
or
dysbiosis,
can
alter
metabolism,
immune
responses,
side
effects.
By
examining
mechanisms
disruption
caused
by
drugs,
this
highlights
specific
case
studies
like
cyclophosphamide,
5-fluorouracil,
irinotecan,
their
impact
microbial
diversity
clinical
also
discusses
microbiome-targeted
strategies,
including
prebiotics,
probiotics,
postbiotics,
fecal
microbiota
transplantation
(FMT),
as
promising
interventions
enhance
treatment.
Furthermore,
potential
profiling
personalizing
therapy
integrating
these
into
practice
is
explored.
Finally,
proposes
future
research
directions,
developing
novel
biomarkers
a
deeper
comprehension
drug-microbiome
interactions,
respond
current
gaps
knowledge
improve
patient
outcomes
care.
Язык: Английский
The Expanding Role of Probiotics in Human Health
Nutrients,
Год журнала:
2025,
Номер
17(7), С. 1116 - 1116
Опубликована: Март 24, 2025
Since
the
1990s,
it
has
been
widely
documented
that
probiotics,
either
alone
or
in
combination
with
prebiotic
supplements,
play
a
vital
role
host
health
and
disease
management
[...].
Язык: Английский
Molecular Mechanisms and Emerging Precision Therapeutics in the Gut Microbiota-Cardiovascular Axis
Cureus,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 26, 2025
A
microbiome
in
the
gut
plays
a
significant
role
cardiovascular
health
and
disease.
Dysbiosis
is
an
imbalance
microbiome,
leading
to
multiple
diseases
(CVD)
such
as
atherosclerosis,
hypertension,
heart
failure.
Gut
microbe-derived
metabolites
trimethylamine-N-oxide
(TMAO)
short-chain
fatty
acids
(SCFAs)
are
important
mediators
of
gut-heart
axis.
Evaluation
relationship
between
host
biomarkers
with
CVD
requires
integration
metagenomics
metabolomics
meta-omics
approaches.
The
literature
review
found
that
microbes
metabolic
signatures
associated
risk
progression
CVD.
development
precision
therapeutic
approaches
for
targeting
microbiota
includes
preventing
adverse
microbial
effects
using
probiotics,
prebiotics,
drug-as-bug
approach
inhibit
harmful
microbiomes,
fecal
transplantation
(FMT).
However,
implication
practice
these
findings
clinical
settings
face
challenges
due
heterogeneity
study
designs,
difficulty
determination
causality,
impact
confounding
factors
diet,
medication,
potential
inter-individual
variability.
Future
researchers
recommended
conduct
longitudinal
studies
further
establish
both
associations
develop
successful
therapeutics
based
on
treatment
Язык: Английский